Gerald L. Andriole, MD

Gerald L. Andriole, MD

Barnes-Jewish Hospital and Washington University School of Medicine

St. Louis, Missouri

Gerald L. Andriole, Jr., MD, is the Robert K. Royce Distinguished Professor and Chief of Urologic Surgery at Barnes-Jewish Hospital, the Siteman Cancer Center and Washington University School of Medicine in St. Louis, Missouri. Dr. Andriole received his medical degree from Jefferson Medical College in Philadelphia, Pennsylvania. He trained in surgery at Strong Memorial Hospital and the University of Rochester and completed urology residency at Brigham and Women’s Hospital and Harvard Medical School. Subsequently, he was a fellow in Urologic Oncology at the National Cancer Institute in Bethesda, Maryland. Dr. Andriole has over 25 years of consistent contributions in the areas of BPH and prostate cancer screening and prevention research. He has contributed well over 300 peer-reviewed publications and abstracts and serves on the editorial boards of several prestigious journals. He is Chairman of the Prostate Committee of the National Cancer Institute’s Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial and is on the Steering Committee of the REDUCE Prostate Cancer Prevention Trial. He is a member of the American Urological Association, American Association for Cancer Research, the American Society of Clinical Oncology, American Surgical Association and the American Association of Genitourinary Surgeons among other societies.

Articles by Gerald L. Andriole, MD

Prostate Cancer Screening: Who? Why? How?

Gerald Andriole, MD, discusses the limitations and successes in the design of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) and European Randomized Study of Screening for Prostate Cancer (ERSPC) trials. He also emphasizes the importance of patient selection in PSA screening and utilizing other diagnostic methods.

Read More

Updates on the ERSPC and the PLCO Trials

Dr. Gerald L. Andriole, MD, reviews the designs, materials, and outcomes of the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (PLCO) and The European Randomized Study of Screening for Prostate Cancer (ERSPC). He distinguishes between legitimate concerns and inappropriate criticisms of the trials. Also, he explains what this means for the practice of PSA testing.

Read More
  • 1
  • 2

Join the GRU Community

- Why Join? -